The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Multisociety Lifelong Learning Statement focuses on learning competencies necessary for advanced heart failure and transplant cardiology specialists.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.
Exposure to air pollution may be associated with increased patient mortality after heart transplantation.
Five-year survival benefit following heart transplant varies widely across transplant centers.
Estimated mortality hazard ratio 1.43 per 10 µg/m³ increment increase in annual PM2.5 exposure
Early observations show lower waitlist mortality, but higher posttransplant mortality or retransplantation.
Although an independent association was not identified between pulmonary vascular resistance and conditional 1-year mortality, it was identified between pulmonary vascular resistance and 30-day mortality.
In the context of cardiac surgery, there is no indication of a “July effect,” describing worse outcomes in the first month of training.
Transfusing red blood cells into cardiac surgery patients only when their hemoglobin levels fall to below 7.5 g/dL does not increase acute kidney injury risk.